Nat Med:氧化剂有助于维持健康的血压

2012-01-29 MedSci MedSci原创

 MedSci评论:  科学是辩证的,人体内许多分子或进化中许多行为,都有其可取之处!而有时,我们容易将某种分子或行为定性为“坏分子”,如氧自由基,寄生虫等,其实,它们同样有可能是两面的!氧自由基对于激活机体许多保护行为,至关重要!而寄生虫却有助于机体建立免疫耐受,减轻多种过敏。类似例子还非常多,如免疫抑制剂雷帕霉素却能抑制多种肿瘤(以往认为这些药物是不能用于肿瘤的)

 MedSci评论:

 科学是辩证的,人体内许多分子或进化中许多行为,都有其可取之处!而有时,我们容易将某种分子或行为定性为“坏分子”,如氧自由基,寄生虫等,其实,它们同样有可能是两面的!氧自由基对于激活机体许多保护行为,至关重要!而寄生虫却有助于机体建立免疫耐受,减轻多种过敏。类似例子还非常多,如免疫抑制剂雷帕霉素却能抑制多种肿瘤(以往认为这些药物是不能用于肿瘤的),睡眠能促进记忆(以往认为GABA会抑制学习和记忆),抗凝剂能促进肿瘤移还是抑制肿瘤的发生?胆酸是人体的“废物”,却发现能杀灭肿瘤细胞;人体产生的很多“代谢废物”还会不会在机体反馈中扮演重要角色?如尿酸,肌酐就没有任何“有益”成分?也许再过一些年,人们就会意识到这些代谢废物也许还有其它一些用途。

这让人想起妇女生产和哺乳,以前认为剖宫产可以代替生产,现在发现正常的生产具有很多特殊功能:如婴儿胸腔在产道中挤压,能将气道中液体排出,避免出生后的新生儿呼吸窘迫综合征;经过产道时,与产道一些微生物接触,是否有助于建立某些“免疫耐受”功能,减少以后的过敏发生?头部在产道的挤压,是否会产生某种应激,有助于反射的建立?哺乳虽然有碍美观,但是却可以减少妇女的乳腺癌发生......

每一个领域,都有许多有价值的科学命题,值得大家去探索!

 

由伦敦大学国王学院的研究人员领导的一项科学研究表明,氧化剂(一个已知参与老化和癌症发展的分子家族)在机体血压调节中发挥着积极的作用。

该研究由国王学院的Philip Eaton博士领导,由英国心脏基金会(BHF)和医学研究理事会(MRC)共同资助,研究的结果发表在《自然-医学》(Nature Medicine)上。研究显示,氧化剂在化学反应中"窃取"其它分子的电子,这有助于防止高血压

研究人员对携带有蛋白激酶G突变的小鼠进行了观察,蛋白激酶G有助于维持血压的可控性。他们发现,携带有突变的这些小鼠都患上了高血压,因为它们的蛋白激酶G不能正常地探测氧化剂。这个突变非常小,小到仅改变了蛋白激酶G中的一个原子,但却足以让蛋白停止工作。

国王学院心血管生物化学教授Philip Eaton教授评价说:"我们的工作将有助于改变科学界对氧化剂的看法;有越来越多的证据表明产生于健康细胞中的氧化剂发挥着重要的调节功能。现在,我们已经证实氧化剂在健康机体中降低血压的重要性,站在一个理想的角度从逻辑上推论,一些高血压的发生可能正是由于这条途径停止了正常工作。"

英国心脏基金会(BHF)研究顾问Helene Wilson博士补充道:"情况并不像'氧化剂是坏的'和'抗氧化剂是好的'这么简单。这项小鼠中的研究让我们对人体如何调控血压有了更进一步的了解,第一次证明氧化剂在机体血压调控方面扮演了重要的角色。同时它也突出了开发治疗高血压新药物的潜在靶标,而高血压正是心脏病和中风主要的风险因素。"

该消息由伦敦大学国王学院提供。

Single atom substitution in mouse protein kinase G eliminates oxidant sensing to cause hypertension

Oleksandra Prysyazhna, Olena Rudyk & Philip Eaton

Abstract: Blood pressure regulation is crucial for the maintenance of health, and hypertension is a risk factor for myocardial infarction, heart failure, stroke and renal disease. Nitric oxide (NO) and prostacyclin trigger well-defined vasodilator pathways; however, substantial vasorelaxation in response to agents such as acetylcholine persists when the synthesis of these molecules is prevented. This remaining vasorelaxation activity, termed endothelium-derived hyperpolarizing factor (EDHF), is more prevalent in resistance than in conduit blood vessels and is considered a major mechanism for blood pressure control1, 2, 3, 4. Hydrogen peroxide (H2O2) has been shown to be a major component of EDHF in several vascular beds in multiple species, including in humans5, 6, 7, 8, 9, 10. H2O2 causes the formation of a disulfide bond between the two αsubunits of protein kinase G I-α (PKGI-α), which activates the kinase independently of the NO–cyclic guanosine monophosphate (cGMP) pathway and is coupled to vasodilation11. To test the importance of PKGI-α oxidation in the EDHF mechanism and blood pressure control in vivo, we generated a knock-in mouse expressing only a C42S 'redox-dead' version of PKGI-α. This amino acid substitution, a single-atom change (an oxygen atom replacing a sulfur atom), blocked the vasodilatory action of H2O2 on resistance vessels and resulted in hypertension in vivo.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1879126, encodeId=3ac318e912672, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Nov 10 00:28:00 CST 2012, time=2012-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949353, encodeId=d18d1949353dd, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Mar 30 14:28:00 CST 2012, time=2012-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=3986, encodeId=8bb13986c8, content=I am forever indebted to you for this ifnomriaton., beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ashwini, createdTime=Sun Feb 12 16:24:00 CST 2012, time=2012-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605649, encodeId=8f351605649ed, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jan 31 04:28:00 CST 2012, time=2012-01-31, status=1, ipAttribution=)]
    2012-11-10 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1879126, encodeId=3ac318e912672, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Nov 10 00:28:00 CST 2012, time=2012-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949353, encodeId=d18d1949353dd, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Mar 30 14:28:00 CST 2012, time=2012-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=3986, encodeId=8bb13986c8, content=I am forever indebted to you for this ifnomriaton., beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ashwini, createdTime=Sun Feb 12 16:24:00 CST 2012, time=2012-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605649, encodeId=8f351605649ed, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jan 31 04:28:00 CST 2012, time=2012-01-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1879126, encodeId=3ac318e912672, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Nov 10 00:28:00 CST 2012, time=2012-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949353, encodeId=d18d1949353dd, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Mar 30 14:28:00 CST 2012, time=2012-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=3986, encodeId=8bb13986c8, content=I am forever indebted to you for this ifnomriaton., beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ashwini, createdTime=Sun Feb 12 16:24:00 CST 2012, time=2012-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605649, encodeId=8f351605649ed, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jan 31 04:28:00 CST 2012, time=2012-01-31, status=1, ipAttribution=)]
    2012-02-12 ashwini

    I am forever indebted to you for this ifnomriaton.

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1879126, encodeId=3ac318e912672, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Nov 10 00:28:00 CST 2012, time=2012-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949353, encodeId=d18d1949353dd, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Mar 30 14:28:00 CST 2012, time=2012-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=3986, encodeId=8bb13986c8, content=I am forever indebted to you for this ifnomriaton., beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ashwini, createdTime=Sun Feb 12 16:24:00 CST 2012, time=2012-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605649, encodeId=8f351605649ed, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jan 31 04:28:00 CST 2012, time=2012-01-31, status=1, ipAttribution=)]